Co-Authors
This is a "connection" page, showing publications co-authored by BRITTANY O'BRIEN and NICHOLAS MURPHY.
Connection Strength
1.615
-
Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024 Jan; 331:115604.
Score: 0.239
-
Correction: Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 Oct; 48(11):1699.
Score: 0.237
-
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
Score: 0.230
-
Times Constraints, Lack of Confidence in Treatment, Stigma, and Confidentiality Concerns: Barriers to Care Among First-year Internal Medicine Residents During the COVID-19 Pandemic. J Psychiatr Pract. 2023 01 01; 29(1):11-14.
Score: 0.225
-
Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
Score: 0.222
-
Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
Score: 0.210
-
Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
Score: 0.199
-
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
Score: 0.051